1
Michael Stroetmann: Fibrinogen-containing dry preparation, manufacture and use thereof. Serapharm Michael Stroetmann, Gordon W Hueschen, April 17, 1984: US04442655 (177 worldwide citation)

A dry preparation having a foam-like and, respectively, fleece-like structure obtained by freeze-drying consists, apart from thrombin in at least catalytically active amounts, substantially of approx. 10 to 95% by weight of fibrin and approx. 5 to 90% by weight of fibrinogen. For the preparation the ...


2
Michael Stroetmann: Enriched plasma derivative for advancement of wound closure and healing. Serapharm Michael Stroetmann, Gordon W Hueschen, January 24, 1984: US04427650 (143 worldwide citation)

A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by wei ...


3
Michael Stroetmann: Enriched plasma derivative for enhancement of wound closure and coverage. Serapharm Michael Stroetmann, Gordon W Hueschen, January 24, 1984: US04427651 (130 worldwide citation)

A sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibri ...



Click the thumbnails below to visualize the patent trend.